Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Medtronic PLC (MDT) Price & Performance

Amylx Pharmaceuticals IncTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Medtronic PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Medtronic PLC trades at $90.31 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 44× Amylx Pharmaceuticals Inc's market cap, and Medtronic PLC pays a 3.18% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXMDT
Market Cap
$2.64B$116.07B
Sector
HealthHealth
52-Week High
$24.19$105.35
52-Week Low
$7.82$73.75
Enterprise Value
$2.39B$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

No Aura AI signal available yet.

Medtronic PLC

Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.

The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT